New changes to REMS safety programs will require stronger treatment documentation and oversight.
New changes to REMS safety programs will require stronger treatment documentation and oversight.
Patient engagement can lead to better health outcomes, but not all engagement strategies are equally effective.
The workforce is aging, getting younger, and gaining more women, all at once. What does that mean for claims management?
Congress may soon clear federal restrictions to processing marijuana transactions, while the FDA asks for feedback on handling marijuana products.
Various state and local governments have sued drug developers for the harms of the opioid epidemic, and this could be the first of many settlements.
Phase 3 clinical trials for this non-opioid drug demonstrate significant reductions in pain for osteoarthritis and chronic low-back pain.
Demographic factors such as gender, ethnicity, socioeconomic status, age, and location can impact opioid risks.
Despite having little clinical impact, topical creams continue to be utilized widely in workers’ comp.
Federal lawmakers and administrative agencies continue to investigate how to best lower ever-increasing drug prices.
Can special implants in the brain override paralysis? The FDA believes one day they could.
The FDA created special drug labels to clear a development hurdle and encourage manufacturers.
Dr. Robert Goldberg and Sandy Shtab talk with Risk & Insurance about changing attitudes and policies around medical marijuana, its potential role in reducing reliance on opioids, and what this can mean for payers, employers, patients and PBMs.
Prescribing has doubled since 2003, overdose deaths quadrupled since 1996, and misuse accounts for 20% of benzodiazepine use.
Kentucky, Connecticut, Idaho, and West Virginia proposed bills to make PTSD compensable for first responders.
The opioid prodrug for acute pain will soon be available in both a stronger and weaker dose.
As 2018’s legislative trends continue to spill into 2019, what big initiatives might impact workers’ comp this year?
An analysis of 90,000 private claims explores the relationship between early PT and reduced long-term opioid use in musculoskeletal pain.
Can doctors in certain states refer patients to pharmacies which they partially own?
Will doctors one day prescribe apps meant to drive behavior changes instead of drugs?
The reSET-O app uses cognitive behavioral therapy techniques to assist patients engaged in medication-assisted therapy for opioid dependence.
Formulary and claims management considerations for populations at risk for “mental-only” cases of PTSD.
The American Gastroenterological Association released guidance on properly prescribing medications for OIC.
Marijuana use among adults aged 50-64 tripled from 2002-2014.
Dr. Silvia Sacalis of Healthesystems teamed up with Dr. Adam Seidner of The Hartford for a session at NWCDC – here are 5 key takeaways.
Five-to-ten times stronger than fentanyl, this drug is not for consumer use, and many claim it could worsen the opioid crisis.
Healthesystems’ clinical leaders comment on the collective responsibility of healthcare entities, providers, and legislators to increase efforts that will help stem opioid overprescribing, misuse and overdose.
More states allow for the legalization of recreational and medical marijuana, while others consider insurance reimbursement.
A study of 9,596 claimants who filled an opioid prescription found that 30% were still taking opioids 90 days later.
Join our VP of Clinical Services on December 6th in Las Vegas for a presentation on value-based care in workers’ comp.
The marijuana-derived seizure drug now sits at schedule V, facing far fewer prescribing and dispensing restrictions.
Healthesystems’ VP of Clinical Services offers insight into prescriptions in workers’ comp claims that should raise concerns.
Assembly No. 4505 may solidify precedence recently made by a judge from the Division of Workers’ Compensation.
Common risk factors can increase worker fatigue, leading to more frequent workplace injuries and a loss of productivity.
With an enormous range of initiatives to prevent and treat opioid use disorder, the bill has officially been signed by the President.
Cassipa (buprenorphine and naloxone) sublingual film delivers a new dosage for the treatment of opioid dependence.
Healthesystems’ VP of Clinical Services explains how too many drugs in a claim can cause health concerns, and what can be done to prevent them.
The FDA is working to create new opioid prescribing practices and guidelines, while also shifting drug development priorities for pain medications.
According to 2016-2017 data, over 20% of polypharmacy claims are over 10 years old, with more than 50% of them for patients aged 50 and older.
On average, construction workers are six times more likely to die from an opioid overdose death, more than any other occupation.
Healthesystems’ Chief Medical Officer spoke with WorkCompCentral regarding DEA plans to reduce opioid manufacturing.
NKTR-181 is supposed to offer a lower frequency of opioid side effects. But are more opioids really the solution we need to the opioid crisis?
Healthesystems’ AVP of Advocacy & Compliance explains how regulation has been unable to keep pace with healthcare innovation & technology.
More states cover PTSD without physical injuries for first responders, and 24 states allow PTSD patients to use medical marijuana.
A new wave of drugs that suppress CGRP proteins to reduce migraines could be on the horizon.
Drugs to treat opioid dependence could be approved under new clinical endpoints other than reducing opioid use.
Our Chief Medical Officer and VP of Clinical Services comment on matters such as the use of anticonvulsants to treat pain and opioid prescriptions for inpatients.
Phase 2/3 clinical trial results for Korsuva demonstrate pain relief with fewer side effects.
Millennials are more diverse and more open to alternative therapies, medical marijuana, healthcare technology, and dialogue surrounding psychosocial concerns.
A flurry of recent developments continues to bring the medical marijuana debate front and center, including further legalization, a Senate bill, a drug approval, and more.
In a randomized clinical trial of 460 patients, researchers found the treatment to have similar impact on self-rated disability as standard wound dressing.
Visit Healthesystems in booth #914 to see how we explore the conference’s “Cosmic” theme, and for a chance to win a $250 gift card.
The FDA recently approved drugs to treat opioid dependence, migraines, and rheumatoid arthritis.
Among many findings, JAMA reports that 20% of deaths among those aged 25-34 were opioid-related.
Within the last month, laws have passed in Tennessee, Colorado, South Carolina, Oklahoma, and Hawaii.
Global spending on cancer therapies now exceeds $133 billion.
Our Chief Medical Officer and VP of Clinical Services comment on the clinical use of ecstasy and marijuana.
A newly released draft guidance encourages the development of more sustained-release buprenorphine products.
In-depth reports for 16 different states examine medical payments, costs, duration of disability, and more.
Senate Bill 336 passed with a 44-6 vote and is now headed to the House.
Kratom continues to grow in popularity as a drug for pain and opioid withdrawal, despite concerns from the FDA, CDC and DEA.
